atropine – Medxy AI

Understanding the FDA’s Rejection of SYD-101: Navigating the Challenges in Pediatric Myopia Treatment

By MedXY 11/04/2025

The FDA has rejected Sydnexis's low-dose atropine eye drop SYD-101 for controlling childhood myopia progression despite promising trial results, highlighting challenges in demonstrating long-term efficacy and clinical significance in new pediatric myopia therapies.

Clinical Updates Ophthalmology Pediatrics Specialties

Atropine vs Cyclopentolate: Optimizing Premyopia Diagnosis in Preschool Children

By MedXY 09/28/2025

This study compares atropine and cyclopentolate for cycloplegia in preschoolers, finding atropine leads to less myopic refraction and may reduce premyopia overestimation. It highlights implications for precise refractive diagnosis in young children.

Clinical Updates news Ophthalmology Specialties

Diversified Segmental Defocus Optimization Lenses With and Without Atropine: A New Frontier in Myopia Prevention

By MedXY 09/11/2025

A recent randomized clinical trial demonstrates that diversified segmental defocus optimization (DSDO) spectacle lenses significantly reduce the onset and progression of myopia in children, with or without adjunct low-dose atropine.